Sustaining GAVI-supported vaccine introductions in resource-poor countries

Since 2000, GAVI provided essential support for an unprecedented increase in the use of hepatitis B (HepB) and Haemophilus influenzae (Hib) containing vaccines in resource poor countries. This increase was supported with significant funding from international donors, intended to be time-limited. To...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2011-04, Vol.29 (17), p.3149-3154
Main Authors: Zuber, Patrick L.F, El-Ziq, Ibrahim, Kaddar, Miloud, Ottosen, Ann E, Rosenbaum, Katinka, Shirey, Meredith, Kamara, Lidija, Duclos, Philippe
Format: Article
Language:English
Subjects:
Allergy and Immunology
Babies
Budgets
Communicable Diseases - epidemiology
Costs
Decision-making
Developing Countries
Financing
funding
Haemophilus influenzae
Hepatitis
hepatitis B
Humans
Immunization
Infant
International Cooperation
Mortality
New vaccines
ownership
prices
Public health
Public-Private Sector Partnerships - organization & administration
Public-Private Sector Partnerships - trends
Supplies
Supply
Vaccination - economics
Vaccination - utilization
Vaccines
Vaccines - economics
Vaccines - immunology
Vaccines - supply & distribution
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since 2000, GAVI provided essential support for an unprecedented increase in the use of hepatitis B (HepB) and Haemophilus influenzae (Hib) containing vaccines in resource poor countries. This increase was supported with significant funding from international donors, intended to be time-limited. To assess the sustainability of this important expansion of the global access to vaccines, we reviewed supply chains, financial resources for procurement and decision-making in countries that introduced hepatitis B or Hib vaccines with GAVI support. During the period studied, the types of vaccine products supplied fluctuated rapidly in relationship with the number of suppliers and availability of more combination products. The price of the cheaper vaccines decreased while that of pentavalent DTwP-HepB-Hib remained stable. In average, vaccine introduction was associated with an increase of national programs budget, with new vaccines representing more than half of that increase, while the part of GAVI contributions to the budget went from 25% to 46%. Less than 20% of the vaccine introductions were decided by a national advisory body. Strengthening supply chains, adjusting funding schemes and increasing national ownership will be key to the sustained use of hepatitis B and Hib vaccines and the eventual addition of other important vaccines where they are the most needed.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.02.042